Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin H Voss

Showing results (1-10 of 141) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2022
Up-front Nivolumab With or Without Salvage Ipilimumab Across International Metastatic Database Consortium Risk Groups in Metastatic Clear Cell Renal Cell CarcinomaMartin H Voss
Therapeutic Advances in Medical Oncology|December 6, 2021
Novel emerging biomarkers to immunotherapy in kidney cancerYasser Ged, Martin H Voss
European Urology|September 24, 2024
Management of Kidney Cancer Relapse to Adjuvant Pembrolizumab: Early Insights and Questions for a Newly Emerging SpaceMartin H Voss, Robert J Motzer
Annals of Translational Medicine|October 29, 2019
Systemic therapy for metastatic renal cell carcinoma-is timing everything?Ritesh R Kotecha, Martin H Voss
The New England Journal of Medicine|April 17, 2024
Adjuvant Immunotherapy for Kidney Cancer - A New Strategy with New ChallengesMartin H Voss, Robert J Motzer
JAMA Oncology|October 28, 2016
Perioperative Management of Localized Kidney Cancer: Watching and WaitingMartin H Voss, Robert J Motzer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2016
Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic RiverMartin H Voss, James J Hsieh
Onkologie|September 22, 2011
Paclitaxel, ifosfamide and cisplatin (TIP) beyond its original indication for salvage treatment of germ cell tumorsMartin H Voss, Darren R Feldman
European Urology|February 4, 2018
Genomic Classifiers in Renal Cell CarcinomaA Ari Hakimi, Martin H Voss
Nature Medicine|January 2, 2026
Mechanistic insights make cancer cachexia a targetable syndromeEd Reznik, Martin H Voss, A Ari Hakimi
Pageof 15

Showing results (1-10 of 141) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2022
Up-front Nivolumab With or Without Salvage Ipilimumab Across International Metastatic Database Consortium Risk Groups in Metastatic Clear Cell Renal Cell CarcinomaMartin H Voss
Therapeutic Advances in Medical Oncology|December 6, 2021
Novel emerging biomarkers to immunotherapy in kidney cancerYasser Ged, Martin H Voss
European Urology|September 24, 2024
Management of Kidney Cancer Relapse to Adjuvant Pembrolizumab: Early Insights and Questions for a Newly Emerging SpaceMartin H Voss, Robert J Motzer
Annals of Translational Medicine|October 29, 2019
Systemic therapy for metastatic renal cell carcinoma-is timing everything?Ritesh R Kotecha, Martin H Voss
The New England Journal of Medicine|April 17, 2024
Adjuvant Immunotherapy for Kidney Cancer - A New Strategy with New ChallengesMartin H Voss, Robert J Motzer
JAMA Oncology|October 28, 2016
Perioperative Management of Localized Kidney Cancer: Watching and WaitingMartin H Voss, Robert J Motzer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2016
Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic RiverMartin H Voss, James J Hsieh
Onkologie|September 22, 2011
Paclitaxel, ifosfamide and cisplatin (TIP) beyond its original indication for salvage treatment of germ cell tumorsMartin H Voss, Darren R Feldman
European Urology|February 4, 2018
Genomic Classifiers in Renal Cell CarcinomaA Ari Hakimi, Martin H Voss
Nature Medicine|January 2, 2026
Mechanistic insights make cancer cachexia a targetable syndromeEd Reznik, Martin H Voss, A Ari Hakimi
Pageof 15